Profusa

Profusa is a digital health company developing injectable biosensor hydrogel technology for continuous, real-time biochemical monitoring of tissue oxygen and other analytes in vivo. Its lead product, the Lumee Oxygen platform, is CE Marked in Europe and is being evaluated in clinical and commercial programs for peripheral artery disease, critical limb ischemia, and other vascular conditions. In July 2026 the company filed a Form 8-K announcing a 1-for-25 reverse stock split effective July 7, 2026 to maintain Nasdaq listing compliance, reducing outstanding shares from approximately 13.2 million to roughly 530,000.